Overview A Study of LY3007113 in Participants With Advanced Cancer Status: Completed Trial end date: 2013-12-01 Target enrollment: Participant gender: Summary This study evaluates the safety and tolerability of different doses of an experimental treatment in participants with advanced cancer. Phase: Phase 1 Details Lead Sponsor: Eli Lilly and Company